Clinical trial
A Prospective, Randomized, Double-Blind (Subject and Rater) Controlled Study to Confirm the Effectiveness of Predictix Genetics Antidepressant -Guided Treatment in Adults With Major Depressive Disorder (MDD)
NCT05137197 is registered in ClinicalTrials.gov with Taliaz Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized, Double-Blind (Subject and Rater) Controlled Study to Confirm the Effectiveness of Predictix Genetics Antidepressant -Guided Treatment in Adults With Major Depressive Disorder (MDD)
- Lead sponsor
- Taliaz Ltd.
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- October 4, 2021
- Completion date
- December 31, 2024
- Enrollment
- 354 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.